Molecular biology of prostate cancer

• Published in: Molecular human reproduction 2003-08, Vol.9 (8), p.437-448
• Main Authors: Schulz, W.A., Burchardt, M., Cronauer, M.V.
• Format: Article
• Language: English
• Subjects: Aged; Androgens - metabolism; Biological and medical sciences; Chromosome Aberrations; Epigenesis, Genetic; Gene Expression Profiling; Humans; Key words: androgens/epigenetics/expression profiling/oncogene/tumour suppressor; Male; Medical sciences; Molecular Biology; Nephrology. Urinary tract diseases; Oncogenes; Prostate - anatomy & histology; Prostate - growth & development; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Prostatic Neoplasms - physiopathology; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Tumors of the urinary system; Urinary tract. Prostate gland
• ISSN: 1360-9947; 1460-2407; 1460-2407
• DOI: 10.1093/molehr/gag064

In spite of progress in diagnosis and treatment, prostate cancer has become one of the most frequent lethal cancers in males in many Western industrialized countries. Research on the molecular biology of prostate cancer is expected to reveal those aspects of Western lifestyle contributing to its high incidence with the aims of improving prevention, distinguishing slow‐growing from aggressive clinically relevant cancers, and providing targets for treatment, particularly of locally advanced and of metastatic disease. Traditionally, prostate cancer research focused on androgens. More recently, tumour suppressors and proto‐oncogenes important in other human cancers have been intensely investigated. Current approaches include the search for genes mutated in familial cases, identification of recurrent chromosomal alterations and their associated potential tumour suppressor genes, determination of gene expression profiles characterizing tumour stages and subclasses, and elucidation of the importance of epigenetic alterations. Results from such studies have begun to be translated into the clinic. Further successful transfer of results from molecular biology to the clinic will, however, require integration of the amassed molecular data into a biological framework model of prostate carcinoma.